In lung cancer, overexpression of MEOX2 has been associated with chemoresistance and prognosis, whereas patients with lower MEOX2 expression had shorter survival times in hepatocellular carcinoma and larynx carcinoma [9–12]. This evidence concerns the gene MEOX2 and lung cancer.